ArticleThe oncologist2025
Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies.MedComm · 2026Review
- SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study.Discover oncology · 2026Article
- SMARCA4-deficient thoracic tumor with vascular differentiation requiring superior vena cava reconstruction: a case report.Journal of cardiothoracic surgery · 2026Article
- CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.Frontiers in immunology · 2026Article
- Rare tongue base metastasis from SMARCA4-deficient undifferentiated non-small cell lung carcinoma: a case report.International journal of clinical and experimental pathology · 2026Article
- Thoracic SMARCA4-deficient undifferentiated tumor prone to misdiagnosis as lung adenocarcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Case Report: Synaptophysin-positive SMARCA4-deficient undifferentiated thoracic tumour: a diagnostic pitfall with therapeutic implications.Frontiers in oncology · 2026Article
- CT imaging features of pulmonary SMARCA4-deficient undifferentiated carcinoma: a retrospective case series.Frontiers in oncology · 2026Article
- A New WHO Entity of SMARCB1/INI1-Deficient Undifferentiated Thoracic Tumors: Rare, Aggressive, and Overlooked.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined disease entity characterized by aggressive clinical behavior, diagnostic complexity, and poor prognosis. Given its rarity and heterogeneous histological presentation, establishing a definitive diagnosis can be challenging and relies heavily on comprehensive molecular and immunohistochemical evaluation. Here, illustrating the challenges highlighted by a real-world case, we describe the diagnostic pathway leading to SMARCA4-UT identification and discuss the differential diagnosis of thoracic tumors, relevant molecular evaluations, the molecular basis of SMARCA4-UT, and treatment implications. Recognition of this recently described entity is crucial, as an accurate diagnosis-as demonstrated by our case-can guide effective therapy and facilitate enrollment in targeted clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.